The FDA is requiring manufacturers of GLP-1 receptor agonist therapies to include warnings regarding the risk for nonarteritic anterior ischemic optic neuropathy, according to a drug safety communication.
The agency conducted a review following the publication of a study by Jimena Tatiana Hathaway, MD, MPH, and colleagues in JAMA Ophthalmology in 2024 that found a potential link between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION).
The agency conducted a meta-analysis that included 126 clinical trials across GLP-1 receptor agonist development programs to assess the

CHICAGO — AI-interpreted transthoracic echocardiography reports were noninferior to human interpretations and may substantially cut reading time, according to results of the AI ECHO INSIGHT trial.
In this study, over-reading cardiologists could not distinguish between AI and human drafts, and AI assistance boosted reporting consistency, researchers reported at the American Heart Association Scientific Sessions.
“An echocardiogram ... is the cardiologist’s workhorse method to view the heart to make diagnoses and determine treatments. In current clinical practice, an ultrasound

CHICAGO — Adults with moderate to severe obstructive sleep apnea and overweight or obesity who used the oral GLP-1 orforglipron for 1 year experienced improvements in sleep apnea severity, according to results from the ATTAIN-OSA trials.
Orforglipron (Foundayo, Eli Lilly) also conferred improvement in various cardiometabolic parameters, including weight, high-sensitivity C-reactive protein and blood pressure, researchers reported at the American Heart Association Scientific Sessions.
“These data support the potential use of orforglipron as a promising oral treatment option for moderate to

ORLANDO — Lifestyle medicine should become as routine in primary care as using an otoscope or ophthalmoscope — and community health centers can help make that possible at scale, according to Kyu Rhee, MD, MPP.
Community health centers represent the largest primary care system in the United States, with more than 17,000 sites serving approximately 52 million patients — which translates to about one in seven Americans nationwide or one in three rural Americans, Rhee said during a presentation at the American College of Lifestyle Medicine (ACLM) annual meeting.
Rhee, president and CEO of the

ORLANDO — Obexelimab bested placebo in reducing glucocorticoid toxicity at 52 weeks among a cohort of patients with IgG4-related disease, according to data presented at ACR Convergence.
“Glucocorticoids are very effective in IgG4-related disease, but relapses are common when we taper them, and repeated treatment can lead to substantial toxicity,” Matthew C. Baker MD, MS, associate division chief of immunology and rheumatology at Stanford University, told Healio regarding his presentation. “We wanted to understand whether the reduction in glucocorticoid exposure we

Implementation of long-acting injectables for HIV care is still lacking important administrative and financial infrastructure, according to a study presented at IDWeek.
Long-acting injectables (LAIs) have transformed both HIV prevention and treatment since first introduced in 2021, researchers said. The LAI regimen involves patients receiving injections bimonthly or at even longer intervals, instead of a daily pill. However, healthcare systems have hit some roadblocks in successfully implementing LAIs at scale, the study confirmed.
“What we really wanted to do was look at sites that have

CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported at the American Heart Association Scientific Sessions.
For the TYDAL-TIMI 78 phase 2b trial, researchers evaluated MAR001 (Marea Therapeutics) in doses of 300 mg, 450 mg and 900 mg compared with placebo. The efficacy analysis included 235 participants (mean age, 60.4 years; 39% women) with triglycerides 175 mg/dL or higher (median at baseline, 249.5 mg/dL) and high remnant cholesterol who completed at least one dose

CHICAGO — Survodutide, a novel glucagon/GLP-1 dual agonist, was noninferior to placebo for major adverse cardiovascular events, according to the results of the SYNCHRONIZE-CVOT trial.
SYNCHRONIZE-CVOT, presented at the American Heart Association Scientific Sessions and simultaneously published in The Lancet, compared survodutide (Boehringer Ingelheim) 3.6 mg once weekly, survodutide 6 mg once weekly and placebo for CV outcomes in adults with obesity or overweight and established cardiovascular disease, chronic kidney disease and/or at least two weight-related complications or risk

To keep up with COPD research and care developments, the 2027 Global Initiative for Chronic Obstructive Lung Disease report features one new section and several updated/revised sections.
Claus F. Vogelmeier, MD, head of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) science committee and head of the respiratory department at Philipps University of Marburg, presented key updates of the report during the 2026 GOLD International COPD conference.
Vogelmeier noted that the final version of the report will be published on World COPD Day, Nov. 18.
Last year, Healio reported on key

Every ophthalmologist will see patients with migraine, and in some cases, the ophthalmologist may be the first doctor patients consult if visual symptoms predominate.
For this reason, we all need to have a good understanding of the symptoms and signs of migraine and our role in a patient’s care.
Visual aura precedes a migraine in about 30% of patients. This results from hyperactivity in the brain and usually starts with scintillating scotomas, flickering or shimmering that slowly expands with a zigzag expanding edge. Flashing lights, blind spots, tunnel vision, distorted or wavy vision,